Spark Therapeutics, Inc. (NASDAQ:ONCE)‘s stock had its “buy” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Friday. Cantor Fitzgerald also issued estimates for Spark Therapeutics’ FY2017 earnings at ($7.27) EPS and FY2018 earnings at ($5.54) EPS.

Several other equities analysts have also issued reports on the company. Evercore ISI assumed coverage on Spark Therapeutics in a research report on Wednesday, August 16th. They issued an “in-line” rating and a $83.00 price objective for the company. Chardan Capital upgraded Spark Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $60.00 to $100.00 in a research report on Tuesday, August 8th. Zacks Investment Research lowered Spark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Stifel Nicolaus reiterated a “buy” rating and issued a $92.00 price objective (up from $77.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Finally, Cowen and Company reiterated an “outperform” rating and issued a $95.00 price objective (up from $75.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating to the stock. Spark Therapeutics currently has an average rating of “Buy” and a consensus target price of $82.32.

Spark Therapeutics (NASDAQ:ONCE) opened at 80.37 on Friday. The firm’s market cap is $2.51 billion. The stock has a 50 day moving average of $71.59 and a 200-day moving average of $61.05. Spark Therapeutics has a 52-week low of $35.07 and a 52-week high of $83.19.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.75) by $0.14. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. During the same quarter in the prior year, the firm posted ($1.04) earnings per share. Spark Therapeutics’s revenue for the quarter was up 14.7% compared to the same quarter last year. On average, analysts expect that Spark Therapeutics will post ($7.75) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://theolympiareport.com/2017/08/27/spark-therapeutics-inc-once-stock-rating-reaffirmed-by-cantor-fitzgerald.html.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 21,350 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $80.01, for a total value of $1,708,213.50. Following the sale, the chief executive officer now owns 251,350 shares in the company, valued at approximately $20,110,513.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Barge Joseph La sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $55.00, for a total value of $275,000.00. Following the completion of the sale, the general counsel now owns 9,567 shares in the company, valued at approximately $526,185. The disclosure for this sale can be found here. Insiders sold a total of 360,660 shares of company stock worth $25,495,351 in the last 90 days. Company insiders own 7.30% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Teachers Advisors LLC boosted its stake in Spark Therapeutics by 16.8% in the fourth quarter. Teachers Advisors LLC now owns 33,884 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 4,875 shares during the last quarter. Nationwide Fund Advisors boosted its stake in Spark Therapeutics by 2.5% in the first quarter. Nationwide Fund Advisors now owns 17,298 shares of the biotechnology company’s stock valued at $923,000 after buying an additional 414 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Spark Therapeutics by 131.8% in the first quarter. Wells Fargo & Company MN now owns 522,894 shares of the biotechnology company’s stock valued at $27,891,000 after buying an additional 297,277 shares during the last quarter. Tocqueville Asset Management L.P. boosted its stake in Spark Therapeutics by 10.1% in the first quarter. Tocqueville Asset Management L.P. now owns 59,850 shares of the biotechnology company’s stock valued at $3,192,000 after buying an additional 5,500 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in Spark Therapeutics by 0.7% in the first quarter. American Century Companies Inc. now owns 488,519 shares of the biotechnology company’s stock valued at $26,058,000 after buying an additional 3,445 shares during the last quarter. Hedge funds and other institutional investors own 87.30% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.